CVS Caremark to buy Apria’s infusion business for $2.1 billion-Reuters

(Reuters) – CVS Caremark Corp said on Wednesday it was buying Coram LLC, Apria Healthcare Group Inc’s specialty infusion services and enteral nutrition business unit, for $2.1 billion.

CVS, which operates a drugstore chain and a pharmacy benefits management unit, said Coram would add $1.4 billion to revenues in the first year after the deal closes and 3 to 5 cents per share to CVS’s adjusted earnings per share in 2015. CVS expects the deal to close in the first quarter of 2014.

Infusion therapy involves administering medication through a needle or catheter when a patient’s condition is too severe to be treated effectively by oral medications.